GO:0004912 interleukin-3 receptor activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0004912 (interleukin-3 receptor activity) is a molecular function defined as combining with interleukin-3 (IL-3) and transmitting the signal across the membrane to initiate a change in cell activity.
• The IL-3 receptor is a heterodimeric cytokine receptor composed of a ligand-specific alpha subunit (IL3RA/CD123) and a shared common beta subunit (CSF2RB/CD131) that also serves IL-5 and GM-CSF receptors.
• IL-3 signaling is a central regulator of hematopoiesis, controlling survival, proliferation, and differentiation of hematopoietic progenitor cells.
• The IL-3 receptor alpha chain CD123 is overexpressed in several hematological malignancies, making it a validated therapeutic target for antibody-drug conjugates and CAR-NK cell therapies.
• IL-3 receptor activity extends beyond classical hematopoiesis: a gamma-delta T cell-IL-3 axis controls allergic responses through sensory neurons, and IL-3 receptor inhibition protects against sepsis in preclinical models.
• CRISPR-based knockout, point-mutation, knock-in, and overexpression models enable causal dissection of IL3RA, CSF2RB, and downstream signaling components in disease and immunity.
Description
Interleukin-3 receptor activity (GO:0004912) is the molecular function by which a cell-surface receptor binds interleukin-3 (IL-3) and converts that binding event into an intracellular signal that changes cell behavior. This activity is essential for hematopoiesis, where IL-3 acts as a multilineage colony-stimulating factor that promotes the survival, proliferation, and differentiation of hematopoietic progenitor cells. The receptor is a heterodimer consisting of a ligand-specific alpha subunit (IL3RA, also known as CD123) and a shared common beta subunit (CSF2RB, also known as CD131) that is also used by the IL-5 and GM-CSF receptors. Because the common beta subunit is shared, the structural and signaling principles of the IL-3 receptor exemplify the organizing logic of common beta cytokine receptor complexes. Researchers study GO:0004912 to understand normal blood formation, immune regulation, and the pathogenesis of hematological malignancies and inflammatory diseases. The IL-3 receptor alpha chain CD123 is a clinically validated target in blastic plasmacytoid dendritic cell neoplasm and acute myeloid leukemia, driving development of targeted antibody-drug conjugates and engineered cell therapies. Beyond oncology, IL-3 receptor signaling has been implicated in sepsis and in neuroimmune control of allergic responses, broadening its biomedical relevance.
interleukin-3 receptor activity At A Glance
| GO ID | GO:0004912 |
|---|---|
| GO term | interleukin-3 receptor activity |
| Ontology | molecular_function |
| Synonym | IL-3R, IL-3 receptor activity |
| Definition | Combining with interleukin-3 and transmitting the signal from one side of the membrane to the other to initiate a change in cell activity. |
| Major function | Ligand-specific cytokine receptor activity that initiates intracellular signaling in response to IL-3. |
| Receptor composition | Heterodimer of IL3RA (CD123, ligand-specific alpha chain) and CSF2RB (CD131, shared common beta chain). |
| Primary biology | Regulation of hematopoietic progenitor survival, proliferation, and differentiation. |
| Therapeutic relevance | CD123-targeted antibody-drug conjugates and CAR-NK therapies in hematological malignancies. |
What Is GO:0004912?
In simple terms, interleukin-3 receptor activity is the ability of a receptor on the cell surface to grab IL-3 and pass a signal into the cell. According to the Gene Ontology, GO:0004912 describes the function of combining with interleukin-3 and transmitting the signal from one side of the membrane to the other to initiate a change in cell activity. This activity is mediated by the heterodimeric IL-3 receptor, in which the alpha subunit (IL3RA/CD123) provides ligand specificity and the common beta subunit (CSF2RB/CD131) provides shared signaling capacity with the IL-5 and GM-CSF receptors.
Why Is interleukin-3 receptor activity Important in Cell Biology?
Interleukin-3 receptor activity is important because it sits at the interface between a soluble cytokine and the intracellular signaling machinery that governs blood cell production and immune cell function. Dysregulated IL-3 receptor signaling contributes to leukemogenesis and is exploited therapeutically through CD123-directed agents. In addition, the receptor participates in non-hematopoietic immune circuits, including a gamma-delta T cell-IL-3 axis that controls allergic responses through sensory neurons, and IL-3 receptor inhibition has shown protective effects in experimental sepsis. Understanding GO:0004912 therefore informs both fundamental hematopoiesis research and translational development of targeted immunotherapies.
• Controls survival, proliferation, and differentiation of hematopoietic progenitor cells.
• Provides ligand-specific recognition of IL-3 through the IL3RA/CD123 alpha subunit.
• Shares the common beta subunit (CSF2RB/CD131) with IL-5 and GM-CSF receptors, integrating cytokine signals.
• CD123 is overexpressed in blastic plasmacytoid dendritic cell neoplasm and acute myeloid leukemia, enabling targeted therapy.
• Supports engineering of CAR-NK cells with enhanced anti-AML functionality.
• Participates in a gamma-delta T cell-IL-3 axis that controls allergic responses via sensory neurons.
• IL-3 receptor inhibition protects against sepsis in a rat cecal ligation and puncture model.
• Serves as a paradigm for common beta cytokine receptor complex assembly and signaling.
• Enables CRISPR-based causal studies of IL3RA, CSF2RB, and downstream signaling components.
• Informs biomarker and therapeutic strategies in hematology, oncology, and inflammation.
Molecular Mechanism of interleukin-3 receptor activity
Ligand recognition by the IL3RA alpha subunit
In simple terms: The alpha chain of the receptor is the part that specifically grabs IL-3.
Interleukin-3 receptor activity begins with binding of IL-3 to the ligand-specific alpha subunit IL3RA (CD123). This alpha chain confers specificity for IL-3, distinguishing the IL-3 receptor from related cytokine receptors that share the common beta subunit.
Assembly of the heterodimeric receptor complex
In simple terms: The alpha chain and the common beta chain come together to form a working receptor.
The IL-3 receptor is a heterodimer composed of IL3RA and the shared common beta subunit CSF2RB (CD131). The common beta subunit is also used by the IL-5 and GM-CSF receptors, and structural studies of common beta cytokine receptor complexes have exemplified the organizing principle of this receptor family.
Signal transmission across the membrane
In simple terms: Once IL-3 is bound, the receptor changes shape and sends a signal inside the cell.
Ligand binding by the IL-3 receptor transmits a signal from one side of the membrane to the other, initiating changes in cell activity as defined by GO:0004912. This signaling is central to the biological effects of IL-3 on hematopoietic cells.
Downstream cellular outcomes
In simple terms: The signal leads to changes in how blood progenitor cells survive, grow, and specialize.
IL-3 receptor activity drives survival, proliferation, and differentiation of hematopoietic progenitor cells, establishing IL-3 as a key regulator of hematopoiesis. These downstream outcomes are the physiological readout of GO:0004912 function.
Regulation by receptor inhibition and therapeutic targeting
In simple terms: Blocking the receptor can change disease outcomes, which is why it is a drug target.
Inhibition of the interleukin-3 receptor protects against sepsis in a rat model of cecal ligation and puncture, demonstrating that receptor activity can be pharmacologically modulated in inflammatory disease. In oncology, CD123-targeting antibody-drug conjugates and engineered CAR-NK cells exploit IL-3 receptor biology for therapy.
Key Genes Involved in GO:0004912 interleukin-3 receptor activity
The following genes and proteins are central to interleukin-3 receptor activity (GO:0004912) and its downstream biology.
| Gene | Major Role | Research Relevance |
|---|---|---|
| IL3 | Ligand that binds and activates the IL-3 receptor | Defines the input signal for GO:0004912 |
| IL3RA (CD123) | Ligand-specific alpha subunit of the IL-3 receptor | Therapeutic target in hematological malignancies |
| CSF2RB (CD131) | Shared common beta subunit of IL-3, IL-5, and GM-CSF receptors | Central to common beta cytokine receptor assembly and signaling |
| CSF2 | GM-CSF ligand that signals through the shared common beta subunit | Context for shared receptor biology |
| IL5 | IL-5 ligand that signals through the shared common beta subunit | Context for shared receptor biology |
| JAK2 | Janus kinase associated with cytokine receptor signaling | Downstream signaling component of IL-3 receptor activity |
| STAT5 | Transcription factor activated downstream of cytokine receptors | Mediates transcriptional outputs of IL-3 signaling |
| STAT3 | Transcription factor downstream of cytokine receptor signaling | Contributes to IL-3-driven gene expression |
| PIK3CD | Catalytic subunit of PI3K delta in hematopoietic cells | Downstream survival signaling |
| AKT1 | Serine/threonine kinase in survival pathways | Downstream effector of IL-3 receptor signaling |
| MAPK1 | Mitogen-activated protein kinase | Proliferation signaling downstream of IL-3 receptor |
| MAPK3 | Mitogen-activated protein kinase | Proliferation signaling downstream of IL-3 receptor |
| BCL2L1 | Anti-apoptotic regulator | Survival output of IL-3 signaling |
| MYC | Transcription factor driving proliferation | Proliferative output of IL-3 signaling |
| GATA1 | Transcription factor in hematopoietic differentiation | Differentiation context of IL-3 biology |
| SPI1 (PU.1) | Transcription factor in myeloid development | Myeloid differentiation context |
| CEBPA | Transcription factor in granulopoiesis | Myeloid differentiation context |
How Is interleukin-3 receptor activity Regulated?
Interleukin-3 receptor activity is regulated at multiple levels. Ligand availability controls receptor engagement, and the shared common beta subunit (CSF2RB/CD131) integrates signals from IL-3, IL-5, and GM-CSF, meaning receptor activity is influenced by competing cytokines. Pharmacological inhibition of the IL-3 receptor can modulate inflammatory outcomes, as shown by protection against sepsis in a rat cecal ligation and puncture model. In therapeutic settings, CD123-directed agents and engineered CAR-NK cells alter IL-3 receptor-dependent signaling in malignant cells. Downstream kinase and transcription factor pathways, including JAK-STAT and PI3K-AKT modules, transduce and shape the cellular response to receptor activation.
interleukin-3 receptor activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| IL3RA (CD123) | Acute myeloid leukemia; blastic plasmacytoid dendritic cell neoplasm | CD123-targeted antibody-drug conjugate testing in AML models |
| IL3RA (CD123) | CAR-NK anti-AML functionality | Engineered CAR-NK cells with cytokine secretion |
| IL3RA (CD123) | Sepsis-associated inflammation | Rat cecal ligation and puncture model with receptor inhibition |
| IL3 | Allergic responses via gamma-delta T cell-IL-3 axis | Sensory neuron co-culture and allergic response models |
| CSF2RB (CD131) | Common beta cytokine receptor signaling | Structural and signaling studies of common beta complexes |
Acute myeloid leukemia and CD123-targeted therapy
CD123 (IL3RA), the ligand-specific subunit of the IL-3 receptor, is a therapeutic target in acute myeloid leukemia. Pivekimab sunirine (IMGN632), a CD123-targeting antibody-drug conjugate, has been evaluated in a phase 1/2 study in relapsed or refractory acute myeloid leukemia. This illustrates how IL-3 receptor activity and its alpha subunit are exploited for targeted treatment.
Blastic plasmacytoid dendritic cell neoplasm
Tagraxofusp, a CD123-directed therapy, has demonstrated long-term benefits in patients with blastic plasmacytoid dendritic cell neoplasm. This disease context highlights the clinical importance of the IL-3 receptor alpha chain as a target and the relevance of GO:0004912 biology in hematological malignancies.
Sepsis and inflammatory injury
Inhibition of the interleukin-3 receptor protects against sepsis in a rat model of cecal ligation and puncture, indicating that IL-3 receptor activity contributes to inflammatory pathology and can be therapeutically modulated.
Allergic responses and neuroimmune circuits
A gamma-delta T cell-IL-3 axis controls allergic responses through sensory neurons, demonstrating that IL-3 receptor activity participates in neuroimmune regulation beyond classical hematopoiesis.
From interleukin-3 receptor activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of IL3RA abolish IL-3-dependent signaling? | IL3RA knockout cell lines |
| Does a specific residue in IL3RA mediate ligand binding? | Point-mutation knock-in of IL3RA |
| Can a tagged IL3RA be used to track receptor trafficking? | Tagged knock-in of IL3RA |
| Does overexpression of CD123 enhance leukemic proliferation? | IL3RA overexpression in hematopoietic cell lines |
| Does CSF2RB loss alter shared cytokine signaling? | CSF2RB knockout models |
| Can CD123-targeted therapies be tested in a defined genetic background? | Knock-in and knockout isogenic models |
How to Study the interleukin-3 receptor activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Flow cytometry | Surface CD123/IL3RA expression | Receptor expression profiling in leukemia and immune cells |
| Phospho-flow or immunoblot | JAK-STAT and PI3K-AKT activation | Downstream signaling after IL-3 stimulation |
| CRISPR knockout | Loss-of-function effects | Testing requirement for IL3RA or CSF2RB |
| CRISPR point mutation | Specific residue function | Mapping ligand-binding or signaling motifs |
| CRISPR knock-in | Tagged or reporter receptor | Tracking receptor localization and dynamics |
| Overexpression | Gain-of-function effects | Modeling CD123-driven proliferation |
| Animal disease models | In vivo efficacy and pathology | Sepsis and leukemia models |
| Structural biology | Receptor complex architecture | Understanding common beta cytokine receptor assembly |
Flow cytometry and receptor surface detection
Flow cytometry using CD123-specific reagents allows quantification of IL-3 receptor alpha chain surface expression, which is central to studying GO:0004912 in hematopoietic cells and in CD123-targeted therapeutic contexts.
Cytokine signaling assays
Phosphorylation of JAK-STAT and PI3K-AKT pathway components can be measured after IL-3 stimulation to assess receptor activity and downstream signaling.
CRISPR-based genetic perturbation
Knockout, point-mutation, knock-in, and overexpression models enable causal testing of IL3RA, CSF2RB, and downstream genes in IL-3 receptor biology.
Preclinical disease models
Animal models such as the rat cecal ligation and puncture sepsis model and xenograft models of hematological malignancies allow evaluation of IL-3 receptor inhibition and CD123-targeted therapies.
How CRISPR Can Be Used to Study GO:0004912 interleukin-3 receptor activity
Knockout
CRISPR knockout of IL3RA or CSF2RB can abolish IL-3 receptor activity, providing a clean loss-of-function background to test downstream signaling and therapeutic responses.
Point Mutation
Point mutations introduced into IL3RA or CSF2RB can dissect specific residues required for ligand binding, receptor assembly, or signal transmission across the membrane.
Knock-in
Knock-in of epitope tags or reporters into IL3RA allows tracking of receptor expression, trafficking, and interactions in live cells.
Overexpression
Overexpression of CD123/IL3RA can model the high receptor levels seen in hematological malignancies and test sensitivity to CD123-targeted agents.
How EDITGENE Supports interleukin-3 receptor activity Research
Researchers studying interleukin-3 receptor activity-related genes often need to determine whether a candidate gene is causally involved in receptor signaling, immune regulation, or malignant transformation. EDITGENE provides the CRISPR tools and services required to build isogenic models that answer these questions with rigor.
Contact EDITGENE today to design your custom CRISPR model for interleukin-3 receptor activity research.
Frequently Asked Questions About interleukin-3 receptor activity
What is interleukin-3 receptor activity?
Interleukin-3 receptor activity (GO:0004912) is the molecular function of combining with interleukin-3 and transmitting the signal across the membrane to initiate a change in cell activity.
What genes are involved in interleukin-3 receptor activity?
Key genes include IL3 (the ligand), IL3RA (CD123, the ligand-specific alpha subunit), and CSF2RB (CD131, the shared common beta subunit).
What is the GO ID for interleukin-3 receptor activity?
The GO ID is GO:0004912, classified under the molecular_function ontology.
What are the synonyms for interleukin-3 receptor activity?
Synonyms include IL-3R and IL-3 receptor activity.
Why is CD123 important in leukemia?
CD123 (IL3RA) is overexpressed in several hematological malignancies and is targeted by antibody-drug conjugates such as pivekimab sunirine and by tagraxofusp in blastic plasmacytoid dendritic cell neoplasm.
How is interleukin-3 receptor activity studied?
It is studied using flow cytometry, cytokine signaling assays, CRISPR knockout and knock-in models, and preclinical disease models.
Does interleukin-3 receptor signaling play a role in sepsis?
Yes, inhibition of the interleukin-3 receptor protects against sepsis in a rat model of cecal ligation and puncture.
Is interleukin-3 receptor activity involved in allergic responses?
Yes, a gamma-delta T cell-IL-3 axis controls allergic responses through sensory neurons.
What is the shared common beta subunit?
CSF2RB (CD131) is the common beta subunit shared by the IL-3, IL-5, and GM-CSF receptors, exemplifying common beta cytokine receptor organization.
How can CRISPR help study interleukin-3 receptor activity?
CRISPR knockout, point mutation, knock-in, and overexpression models allow causal testing of IL3RA, CSF2RB, and downstream signaling genes in IL-3 receptor biology.
Conclusion
Interleukin-3 receptor activity (GO:0004912) is a molecular function that links the cytokine IL-3 to intracellular signaling programs controlling hematopoiesis, immune regulation, and disease. Its heterodimeric architecture, shared common beta subunit, and clinically validated alpha chain CD123 make it a central node in both basic and translational research. CRISPR-based models and targeted therapies continue to refine our understanding of this receptor activity in leukemia, sepsis, and allergic inflammation.
References
- 1. Takatsu K. 1992. Interleukin-5.. Curr Opin Immunol 4(3):299-306 PMID: 1418709
- 2. Caveney NA et al.. 2024. Structure of the interleukin-5 receptor complex exemplifies the organizing principle of common beta cytokine signaling.. Mol Cell 84(10):1995-2005.e7 PMID: 38614096
- 3. Ihle JN. 1992. Interleukin-3 and hematopoiesis.. Chem Immunol 51:65-106 PMID: 1567546
- 4. Hu J et al.. 2019. The inhibitor of interleukin-3 receptor protects against sepsis in a rat model of cecal ligation and puncture.. Mol Immunol 109:71-80 PMID: 30870654
- 5. Flayer CH et al.. 2024. A γδ T cell-IL-3 axis controls allergic responses through sensory neurons.. Nature 634(8033):440-446 PMID: 39232162
- 6. Christodoulou I et al.. 2021. Engineering CAR-NK cells to secrete IL-15 sustains their anti-AML functionality but is associated with systemic toxicities.. J Immunother Cancer 9(12) PMID: 34896980
- 7. Daver NG et al.. 2024. Pivekimab sunirine (IMGN632), a novel CD123-targeting antibody-drug conjugate, in relapsed or refractory acute myeloid leukaemia: a phase 1/2 study.. Lancet Oncol 25(3):388-399 PMID: 38423051
- 8. Pemmaraju N et al.. 2022. Long-Term Benefits of Tagraxofusp for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm.. J Clin Oncol 40(26):3032-3036 PMID: 35820082
